Market Newsdesk

NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hub Group, Inc. (“Hub Group” or the “Company”) (NASDAQ: HUBG) on behalf of investors that purchased or otherwise acquired Hub Group securities between April 28, 2023 and May 11, 2026 (the “Class Period”).

CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION

If you are an investor in Hub Group and have suffered losses, you may

CLICK HERE

to contact us. You may also contact Kaplan Fox by emailing

[email protected]

or by calling (646) 315-9003.

DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than August 28, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

On February 5, 2026, Hub Group announced preliminary fourth quarter and full year 2025 results and disclosed the identification of a $77 million accounting error due to “the understatement of purchased transportation costs and accounts payable in the first nine months of 2025.” Additionally, the Company said it “plans to restate its financial statements for the first, second and third quarters of 2025,” and “is continuing to assess the potential impact to its consolidated financial statements for the years ended December 31, 2024 and 2023.”

On this news, the price of Hub Group stock fell $9.37 per share, or 18.25%, to close at $41.96 per share on February 6, 2026.

Then, on May 12, 2026, Hub Group announced that it had “identified certain transactions that were prematurely or incorrectly recognized or not adequately supported,” causing its 2023 and 2024 annual reports filed with the SEC to be “materially misstated,” such that they “should no longer be relied upon.” The Company did not quantify the expected misstatement, although it stated that it “expects to conclude that it did not maintain effective disclosure controls and procedures and internal control over financial reporting for each of the years ended December 31, 2024 and 2023.”

On this news, the price of Hub Group stock fell $5.24 per share, about 12.5%, to close at $36.62 per share on May 12, 2026.

The complaint alleges, among other things, that throughout the Class Period, the Company’s financial statements contained material misstatements caused by the premature and incorrect recognition of certain transactions and other material misstatements caused by the understatement of purchased transportation costs and accounts payable.

WHY CONTACT KAPLAN FOX?

Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.

Kaplan Fox is widely regarded as one of the nation’s premier plaintiffs’ securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.

If you have any questions about this Notice, your rights, or your interests, please contact:

CONTACT:

Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
[email protected]

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
[email protected]

Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.

https://www.kaplanfox.com/case/hub-group-inc/

Quantum X Labs has completed development steps with the NVIDIA CUDA-Q Ecosystem

Tel Aviv, Israel, July 24, 2026 (GLOBE NEWSWIRE) — Quantum X Labs Inc. (Nasdaq: QXL) (“Quantum X” or the “Company”), an advanced technologies company, today announced progress on its technical roadmap for its AI-driven quantum error-correction program.

The work is focused on reviewing QXL’s milestone results and draws on NVIDIA accelerated computing, the NVIDIA CUDA-Q QEC software libraries and, as QXL progresses from simulation-based validation toward hardware-derived syndrome data and future real-time decoding.

QXL has completed two meaningful development steps. First, the Company executed its Deep Quantum Error Correction (DQEC) workflow on an NVIDIA GPU in an AWS environment and benchmarked its transformer-based QECCT decoder against the classical Minimum-Weight Perfect Matching (MWPM) decoder across controlled toric-code noise configurations. QECCT outperformed MWPM in selected simulated regimes.

QXL also tested synthetic surface-code configurations modeled on Google’s public surface-code geometry and experiment structure, spanning multiple code distances. Across these scenarios, the QECCT decoder showed stable logical and bit error rates under varying physical error conditions.

These results are intended as an initial step in validating the approach within controlled simulation environments. Future work is expected to focus on extending these evaluations to publicly available experimental datasets and continuing to refine data pipelines and decoder workflows compatible with CUDA-Q QEC frameworks.

The broader roadmap also includes QXL’s planned work with IQCC, a Quantum Machines company, to generate hardware-derived syndrome data on superconducting quantum processing hardware. QXL is also reviewing where AI-based pre-decoder workflows using NVIDIA Ising, and low-latency optimization can add the greatest value across these stages of QXL’s roadmap.

“These results are meaningful because they move our program from cloud deployment into measured decoder performance and a surface-code data pipeline,” said Prof. Nir Sharon, Chief Quantum Technology Scientist at Quantum X Labs. “We are accelerating QXL’s roadmap with NVIDIA accelerated computing, CUDA-Q QEC and low-latency QEC expertise, while IQCC provides the path to hardware-derived syndrome data. This staged approach is designed to move us from offline benchmarking toward practical real-time QEC.”

QXL’s DQEC technology is based on a proprietary transformer architecture that uses QEC code structure and syndrome information to predict logical corrections. The program is intended to support multiple stabilizer-code workflows and to evaluate the decoder as a full decoder, pre-decoder or hybrid component within accelerated QEC systems.

Quantum X Labs Inc.

Quantum X Labs Inc. and its subsidiaries are focused on quantum technology, digital advertising and computing and enterprise artificial intelligence (AI) solutions. Quantum X Labs Ltd. is focused on developing and promoting quantum algorithms for the transportation, drug discovery and security segments as well as developing quantum- based GPS replacement and quantum atom accuracy solutions. Gix Media develops a variety of technological software solutions, which perform automation, optimization and monetization of internet campaigns, for the purposes of acquiring and routing internet user traffic to its customers. Metagramm is a developer of grammatical error correction software and offers tools for writing and reviewing, grammar, spelling, punctuation and style features, as well as translation and multilingual dictionaries, using artificial intelligence and machine learning technology.

For more information about Quantum X Labs, visit https://quantumxlabs.xyz/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Quantum X Labs’ and its subsidiaries’ strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. For example, the Company is using forward-looking statements when it discusses how its future work is expected to focus on extending evaluations to publicly available experimental datasets and continuing to refine data pipelines and decoder workflows compatible with CUDA-Q QEC frameworks, accelerating QXL’s roadmap with NVIDIA accelerated computing, CUDA-Q QEC and low-latency QEC expertise and moving from offline benchmarking toward practical real-time QEC. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s most recent Annual Report on 10-K and in subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Quantum X Labs is not responsible for the content of third-party websites. 

Investor Relations Contacts:

Michal Efraty
Investor Relations
[email protected] 

BOSTON, July 24, 2026 (GLOBE NEWSWIRE) — Factorial Energy Inc. (Nasdaq: FAC) (“Factorial”), a leading American solid-state battery innovator, today announced its first commercial drone battery order. The order marks Factorial’s entry into commercial aerospace applications.

The order marks Factorial’s first commercial order in the aerospace sector and follows successful battery integration and drone flight testing. Factorial will supply high-energy-density lithium-metal cells for integration into battery packs by a U.S.-based pack integrator, creating a battery cell and pack supply chain designed to support demanding drone applications.

Factorial provides a foundation built to scale across the full breadth of physical AI — drones, autonomous aviation, space, defense, and robotics — and to power a generation of autonomous machines that must carry both their own intelligence and their own energy.

Unlike artificial intelligence operating inside centralized data centers, physical AI is embedded in machines that operate in the real world. Drones, autonomous aircraft, mobile robots, spacecraft, defense platforms, and other intelligent systems must carry both their own computing capability and their own energy. These applications require more than batteries that simply store energy: they require systems that deliver high power, manage heat, operate safely near people and sensitive electronics, and maintain reliability under demanding environmental and mission conditions.

“We are thrilled about this commercial order from the aerospace sector, on the heels of our successful integration and drone flight test that demonstrated a more than 30% increase in flight range,” said Siyu Huang, CEO of Factorial. “It’s a validation that the same rigorous qualification standards behind last year’s 1,200 km record drive and our first vehicle production program now extend into an entirely new field. In only six months, we designed a new product, built integration partnerships on three continents, completed flight testing, and secured a first purchase order. That is the strategy working as designed. We are committed to building the foundational energy layer that will underpin the next era of mobility and artificial intelligence. Humanity deserves better batteries, and delivering them is our mission.”

As batteries become critical infrastructure for autonomous and intelligent systems over the next decade, Factorial is positioning its technology to serve a broad and rapidly expanding marketplace. According to a March 2026 report by the strategy consulting business unit of PricewaterhouseCoopers (PwC), the global Physical AI market is projected to reach approximately €430 billion by 2030, with significant upside potential as systems that operate in the real, physical world continue to scale and mature.

About Factorial Energy Inc.

Factorial Energy (Nasdaq: FAC) is a leading American solid-state battery innovator backed by IQT – the not-for-profit strategic investor for the U.S. national security community and America’s allies – and Mercedes-Benz, Stellantis, Hyundai, and Kia. Through its proprietary FEST® and Solstice™ platforms, engineered for scalable manufacturing, Factorial delivers industry-leading performance across aerospace, energy storage and mobility applications. Mercedes-Benz’ real-world road testing in a lightly modified test vehicle achieved over 1,200 km of range on a single charge, while Stellantis-lab testing verified 77 Ah cells demonstrating high energy density, fast-charging, and robust use for energy and power performance across temperature extremes with the technology successfully integrated into a Dodge Charger Daytona demonstration vehicle. For more information visit www.factorialenergy.com.

Forward-Looking Statements

Certain statements in this communication may be considered “forward-looking statements.” Forward-looking statements herein generally relate to future events or the future financial or operating performance of Factorial. For example, Factorial’s expectations regarding future financial performance, manufacturing capabilities and operations, Factorial’s business plans, and other projections concerning key performance metrics or milestones are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “project,” “target,” “plan,” or “potentially” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. While Factorial may elect to update such forward-looking statements in the future, it disclaims any obligation to do so.

Factorial IR Contact: [email protected]
Factorial Media Contact: [email protected]

CEO Discusses Why the Future of Cancer Treatment May Belong to Combination Approaches and How ERNA-101 Was Designed to Turn Immunologically “Cold” Tumors Into Targets for the Immune System

Video Showcases Differentiated Off-the-Shelf Cell Therapy Platform, Independent Validation of Complete Tumor Clearance in Preclinical Studies and Continued Execution Toward Planned IND Submission in Q3 2026

Access the Ernexa CEO Corner

here
 

CAMBRIDGE, Mass., July 24, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today released a new installment of its CEO Corner series featuring President and Chief Executive Officer Sanjeev Luther, who discusses why many of the next major advances in oncology may come from intelligently combining therapies with complementary mechanisms of action and how Ernexa believes ERNA-101 was intentionally designed to play an important role within that evolving treatment paradigm.

As immunotherapies and antibody-drug conjugates (ADCs) continue transforming cancer treatment, many solid tumors remain resistant because they evade immune detection. In the video, Mr. Luther explains how ERNA-101 was specifically engineered to address one of oncology’s most significant remaining challenges, the immunosuppressive tumor microenvironment and why the Company believes its novel off-the-shelf cell therapy has the potential to enhance the effectiveness of existing immunotherapies rather than compete with them.

The discussion also highlights Ernexa’s growing body of encouraging preclinical data, differentiated allogeneic induced mesenchymal stem cell (iMSC) platform, and continued operational execution as the Company advances toward becoming a clinical-stage biotechnology company.

“Cancer treatment continues to evolve, but one of the biggest opportunities still lies ahead helping more patients benefit from the therapies that already exist,” said Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics. “We believe the future of oncology will increasingly rely on combination therapies that attack cancer from multiple angles, and ERNA-101 was intentionally designed to play that role. By targeting the tumor microenvironment and helping activate an immune response within the tumor itself, we believe ERNA-101 has the potential to work alongside today’s leading immunotherapies and address one of the biggest remaining challenges in solid tumors. Our CEO Corner provides investors with an inside look at the science supporting this strategy, the compelling preclinical data we’ve generated, and the meaningful progress we’re making as we advance toward our planned IND submission and first-in-human clinical study.”

During the CEO Corner, Mr. Luther explains how Ernexa’s proprietary allogeneic, off-the-shelf iMSC platform enables ERNA-101 to selectively home to tumors, deliver its therapeutic payload directly within the tumor microenvironment, and potentially convert immunologically “cold” tumors into tumors that can be recognized and attacked by the immune system.

The video also reviews compelling preclinical data supporting this differentiated approach, including:

• Complete tumor elimination and 100% long-term survival in an initial ovarian cancer study when ERNA-101 was combined with PD-1 blockade.
• Independent validation demonstrating complete tumor clearance and durable long-term survival in approximately two-thirds of treated animals, while no complete responses were observed in untreated controls or either monotherapy group, reinforcing the potential value of ERNA-101 as a combination therapy.

Mr. Luther also provides investors with an operational update, highlighting that Ernexa has completed manufacturing process development, initiated engineering batch production, continues advancing IND-enabling activities, and remains on track for its planned IND submission in the third quarter of 2026 followed by an anticipated Phase 1 clinical study in the fourth quarter of 2026.

The discussion concludes with Ernexa’s commercial strategy, initially targeting the approximately 15,000 women diagnosed annually in the United States with platinum-resistant ovarian cancer, while recognizing the opportunity to potentially expand into the significantly larger platinum-sensitive ovarian cancer population as clinical development progresses.

The Ernexa CEO Corner is now accessible on the Company’s website and social media channels. Access it here.

For more information about ERNA-101 and the Company’s development plans, visit www.ernexatx.com

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.

For more information, visit www.ernexatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “objective,” or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Ernexa’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa’s risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law.

Media Contact

Sharon Golubchik
RAYNZ
[email protected]

Investor Contact

Jenene Thomas
JTC Team, LLC
(908) 824-0775
[email protected]

Two additional recurring commercial programs increase estimated annualized commercial activity to more than $1.09 billion while further expanding Vivakor Supply & Trading’s physical crude oil marketing platform.

Dallas, TX, July 24, 2026 (GLOBE NEWSWIRE) — Vivakor, Inc. (Nasdaq: VIVK) (“Vivakor” or the “Company”), through its wholly owned subsidiary Vivakor Supply & Trading, LLC (“VST”), today announced the execution of two new recurring physical crude oil commercial programs expected to generate approximately $384 million of annualized commercial activity, increasing the Company’s announced physical crude oil marketing platform to more than $1.09 billion of annualized commercial activity, based on current market pricing assumptions.

The new commercial programs consist of two recurring physical crude oil purchase and sale transactions at the Cushing and Midland Terminals and further expand VST’s recurring physical crude oil marketing activities. The agreements reflect the Company’s continued execution of its strategy to build a scalable, integrated commercial marketing platform that complements its transportation, terminaling and storage operations.

Key Highlights

• Additional Annualized Commercial Activity: Approximately $384 million
• Commercial Platform: More than $1.09 billion
• New Commercial Programs: Two
• Additional Marketed Volume: 400,000 barrels per month (4.8 million barrels annually)
• Location: Cushing and Midland Terminals
• Contract Term: August 1, 2026 – July 31, 2027

*Based on current market pricing assumptions. Actual commercial activity will vary based on commodity prices, market differentials, delivered volumes and timing.

“Surpassing $1 billion of announced annualized commercial activity marks an important milestone in the continued growth of Vivakor Supply & Trading,” said James Ballengee, Chairman, President and Chief Executive Officer of Vivakor. “The continued expansion of our recurring commercial programs reflects the strength of our commercial relationships and our ability to consistently originate and execute physical crude oil transactions. As we build additional scale across our marketing platform, we believe we are creating a business that complements our transportation, terminaling and storage operations while supporting long-term shareholder value.”

Consistent with standard physical commodity marketing transactions, VST only recognizes a small percentage of the total contract value as gross profit, reflecting its role as an intermediary in the physical crude oil supply chain. Accordingly, the gross profit recognized by VST will represent only a portion of the estimated commercial activity described above and will vary based on market conditions, commodity pricing, transaction structure and delivered volumes.

About Vivakor, Inc.

Vivakor, Inc. is an integrated provider of sustainable energy transportation, storage, reuse, and remediation services, operating one of the largest fleets of oilfield trucking services in the continental United States. Its corporate mission is to develop, acquire, accumulate, and operate assets, properties, and technologies in the energy sector. Vivakor’s integrated facilities assets provide crude oil, storage, transportation, reuse, and remediation services under long-term contracts. Once operational, Vivakor’s interest in oilfield waste remediation facilities will facilitate the recovery, reuse, and disposal of petroleum byproducts and oilfield waste products.

For more information, please visit our website: http://vivakor.com

Cautionary Statement Regarding Forward-Looking Statements

This news release may contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements. Forward-looking statements may be identified but not limited by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” and variations or similar expressions. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including, but not limited to, the expected transaction and ownership structure, the valuation of the transaction, the likelihood and ability of the parties to successfully and timely consummate planned acquisitions, the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect Vivakor or the expected benefits of the such transaction, our ability to maintain the listing of our securities on The Nasdaq Capital Market, the parties failure to realize the anticipated benefits of pending transactions, disruption and volatility in the global currency, capital, and credit markets, changes in federal, local and foreign governmental regulation, changes in tax laws and liabilities, tariffs, legal, regulatory, political and economic risks, our ability to successfully develop products, rapid change in our markets, changes in demand for our future products, and general economic conditions.

These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor’s filings with the U.S. Securities and Exchange Commission, which factors may be incorporated herein by reference. Actual results, performance or achievements may differ materially, and potentially adversely, from any projections and forward-looking statements and the assumptions on which those forward-looking statements are based. There can be no assurance that the data contained herein is reflective of future performance to any degree. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance as projected financial information and other information are based on estimates and assumptions that are inherently subject to various significant risks, uncertainties and other factors, many of which are beyond our control. All information set forth herein speaks only as of the date hereof in the case of information about Vivakor and the Endeavor Entities or the date of such information in the case of information from persons other than Vivakor and the Endeavor Entities, and we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication. Forecasts and estimates regarding the Endeavor Entities industries and markets are based on sources we believe to be reliable; however, there can be no assurance these forecasts and estimates will prove accurate in whole or in part.

Investor Contact:

P:469-480-7175
[email protected]